Instrument Inactif

Communiqués NeoGenomics, Inc. OTC Bulletin Board

Actions

US64049M2098

Installations et services en soins de santé

Cours en clôture OTC Bulletin Board
- ^USD	-

26/08	NeoGenomics obtient une extension de la couverture Medicare pour le suivi de l'immunothérapie avec RaDaR ST	MT
11/08	NeoGenomics, Inc. annonce la démission d'Alicia Olivo de son poste de directrice juridique, effective au 21 septembre 2026	CI

Communiqués

26/08	NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring	BU
28/07	NeoGenomics: Q2 Earnings Snapshot	AQ
28/07	NeoGenomics Reports Second Quarter 2026 Results	BU
20/07	NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS	BU
09/07	NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer	BU
07/07	NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026	BU
25/06	NeoGenomics Appoints Carolyn Starrett to its Board of Directors	BU
17/06	NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes	BU
15/06	NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes	BU
26/05	NeoGenomics to Present New Research at ASCO Annual Meeting 2026	BU
18/05	NeoGenomics to Participate in Upcoming Investor Conferences	AQ
15/05	NeoGenomics to Participate in Upcoming Investor Conferences	BU
05/05	Southern District Of New York Grants Motion To Dismiss Securities Class Action Against Cancer Diagnostics Company With Prejudice	AQ
28/04	NeoGenomics : Investor Presentation – April 2026	PU
28/04	NeoGenomics: Q1 Earnings Snapshot	AQ
28/04	NeoGenomics Reports First Quarter 2026 Results	BU
23/04	NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration	BU
13/04	NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026	BU
07/04	NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026	BU
16/03	NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling	BU
10/03	NeoGenomics : Investor Presentation – March 2026	PU
25/02	NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types	BU
18/02	NeoGenomics to Participate in Upcoming Investor Conferences	BU
17/02	NeoGenomics : Investor Presentation – February 2026	PU
17/02	NeoGenomics: Q4 Earnings Snapshot	AQ